IAVI C003

Status:Completed
Phase:I
Principal Investigator(s):
Objective:A study to evaluate the safety and immunogenicity of a single dose of MVA expressing HIV-1 clade C env/gag-pol and nef-tat fusion genes  (ADMVA).
Prevention Option(s):HIV Vaccine
Study Design:
Arms and Assigned Interventions
DescriptionADMVA administered to volunteers who previously received three doses of a clade C DNA Vaccine ADVAX e/g + ADVAX p/n-t
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code: IAVI C003
Trial Sponsors: Aaron Diamond AIDS Research Center, University of Rochester Medical Center
Start Date
End Date
none
none
Enrollment:8
Age range: ↔ any
Population: